Holen Sie sich die Stockscreener-App
365.08
8.33%
28.08
Schlusskurs vom Vortag:
$337.00
Offen:
$365.08
24-Stunden-Volumen:
103
Relative Volume:
0.43
Marktkapitalisierung:
$9.76B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+31.80%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$244.54
$365.08
Bio-Rad Laboratories, Inc. Class B Stock (BIO.B) Company Profile
Firmenname
Bio-Rad Laboratories, Inc. Class B
Sektor
Branche
Telefon
-
Adresse
-
Compare BIO.B vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO.B
Bio-Rad Laboratories, Inc. Class B
|
365.08 | 9.76B | 0 | 0 | 0 | 0.00 |
ABT
Abbott Laboratories
|
101.82 | 176.19B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.93 | 117.59B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
282.60 | 108.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.84 | 63.53B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.39 | 49.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio-Rad Laboratories, Inc. Class B Aktie (BIO.B) Neueste Nachrichten
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - tradingview.com
Bio-Rad Laboratories Inc Stock Intrinsic Values | HAM:BUWA - gurufocus.com
Bio-Rad Laboratories Inc Stock Baskets - gurufocus.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - Zacks Investment Research
Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities - GlobeNewswire Inc.
Magnetic Bead Purification Kits Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Starbucks Upgraded, Ralph Lauren Downgraded: Updated Rankings on Top Blue-Chip Stocks - investorplace.com
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bio-Rad Laboratories Inc. Class A (BIO) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Koninklijke Philips N.V. NY Registry SharesADR Peer Comparison – Compare with Others - Value Research
Bio-Rad Laboratories (NYSE: BIO) exec vests 246 RSUs, withholds shares - Stock Titan
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - The Motley Fool
Bio-Rad Reports First-Quarter 2026 Financial Results - Investing News Network
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 - BioSpace
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 - Investing News Network
Bio-Rad Reports Third-Quarter 2025 Financial Results - Investing News Network
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 - Investing News Network
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies - Business Wire
Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination - Morningstar
Bio-Rad Laboratories, Inc. (BIO.B) Führung & Management Team Analyse - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Bio-Rad Laboratories, Inc. (BIO.B) Company Information - Simply Wall Street
Finanzdaten der Bio-Rad Laboratories, Inc. Class B-Aktie (BIO.B)
Es liegen keine Finanzdaten für Bio-Rad Laboratories, Inc. Class B (BIO.B) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):